Open database of authors and journals




Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

BioDrugs, 2020, 34, 197-207

Citation of paper, Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54-78 Data From a Randomized, Double-Blind, Phase III Trial

Authors Citing This Paper

AuthorCiting PapersAuthor's PapersAuthor's CitationsAuthor's IF
Ji-Won Kim1181413.2
Ju-Yang Jung1243253.8
Chang Hee Suh11994,1792.8

Journals Citing This Paper

JournalCiting PapersJournal's IFJournal's Star
Advances in Therapy14.1★★
Expert Opinion on Biological Therapy15.4★★

Similar Articles

Quick Tips
This is an overview of where and by who this paper has been cited.
Help Us
Non-profit projects normally ask for donations. We don't. We will survive one way or another. If you wish to help us, please spread the word to let more people use this service.

It is delightful to see our efforts are useful to a broad range of researchers.
EXALY
Profiles
Fields
Search Engines
Tools